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Background: Few studies have simultaneously compared the impacts of pharmacotherapy and mental diagnoses
on metabolic syndrome (MetS) among psychiatric outpatients with mood and anxiety disorders. This study aimed
to investigate the impacts of pharmacotherapy and mental diagnoses on MetS and the prevalence of MetS among
these patients.
Methods: Two-hundred and twenty-nine outpatients (men/women = 85/144) were enrolled from 1147 outpatients
with mood and anxiety disorders by systematic sampling. Psychiatric disorders and MetS were diagnosed using the
Structured Clinical Interview for DSM-IV-TR and the new International Diabetics Federation definition, respectively.
The numbers of antipsychotics, mood stabilizers, and antidepressants being taken were recorded. Logistic regression
was used to investigate the impacts of pharmacotherapy and psychiatric diagnoses on MetS.
Results: Among 229 subjects, 51 (22.3%) fulfilled the criteria for MetS. The prevalence of MetS was highest in
the bipolar I disorder (46.7%) patients, followed by bipolar II disorder (25.0%), major depressive disorder (22.0%),
anxiety-only disorders (16.7%), and no mood and/or anxiety disorders (14.3%). The percentages of MetS among the
five categories were correlated with those of the patients being treated with antipsychotics and mood stabilizers.
Use of antipsychotics and/or mood stabilizers independently predicted a higher risk of MetS after controlling for
demographic variables and psychiatric diagnoses. When adding body mass index (BMI) as an independent
variable in the regression model, BMI became the most significant factor to predict MetS.
Conclusion: BMI was found to be an important factor related to MetS. Pharmacotherapy might be one of
underlying causes of elevated BMI. The interactions among MetS, BMI, pharmacotherapy, and psychiatric
diagnoses might need further research.
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Metabolic syndrome (MetS) is characterized by several
cardiovascular risk factors, including central obesity, hy-
perglycemia, dyslipidemia and hypertension, which are
related to increased risks of cardiovascular diseases and
type 2 diabetes mellitus [1,2]. The association between
these metabolic disorders and the development of cardio-
vascular diseases might be multi-factorial, such as insulin
resistance, oxidative stress, low-grade inflammation and
vascular mal-adaptation [1,2]. Some studies have indicated
an association between brain dysfunction and the patho-
genesis of metabolic syndrome [3]. In recent years, many* Correspondence: Liucy752@cgmh.org.tw
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reproduction in any medium, provided the orstudies have investigated the prevalence of MetS among
psychiatric patients. Most studies have focused on patients
with schizophrenia or bipolar I disorder, and found that
the two disorders carry a higher risk of MetS [4-8]. This
may partially result from the fact that these patients are
often treated with antipsychotics or mood stabilizers,
some of which are associated with weight gain and abnor-
mal lipid indices [8-10]. Moreover, other factors might
also have an impact on MetS, such as lifestyle and shared
features of hormonal, immunologic, and autonomic ner-
vous system dysregulation between mental disorders and
MetS [5,11,12].
Major depressive disorder (MDD) has been reported to
be associated with MetS [13-17]. Some studies have dem-
onstrated that depressive symptoms noted at baselinetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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pathophysiology has been reported between MDD and
MetS [13], and some antidepressants are also related to
weight gain [9,10]. In recent years, several new-generation
antipsychotics have been used as an augmentation therapy
for treatment-resistant MDD [18], which also increases
the risk of MetS among MDD outpatients.
Compared with schizophrenia, bipolar I disorder and
MDD, MetS among patients with anxiety disorders has
received less attention. There are conflicting results re-
garding the relationship between MetS and anxiety symp-
toms or disorders. Some studies have reported a null
finding regarding this relationship [19-21], while one study
reported a positive finding between generalized anxiety
disorder (GAD) and MetS [22]. Moreover, most studies
have been concerned with the relationship between
anxiety symptoms and MetS, and fewer studies have
focused on the relationship between anxiety disorders
and MetS [22,23].
Although many studies have reported the relationships
between mental disorders and MetS, schizophrenia and
bipolar I disorder have received more attention in this
regard than MDD and anxiety disorders. To the best of
our knowledge, no study has simultaneously investigated
the prevalence of MetS in different mood and anxiety
disorders and the impacts of mental diagnoses and
pharmacotherapy on the risk of MetS among psychiatric
outpatients with mood and anxiety disorders. Therefore,
the aims of this study were to investigate the impacts of
pharmacotherapy and mental diagnoses on the risk of
MetS and the prevalence of MetS among psychiatric
outpatients with mood and anxiety disorders. The above
issues are important because understanding the impacts
of mental disorders and pharmacotherapy on MetS pro-
vides evidence and strategies regarding how to prevent
MetS. Moreover, investigating the prevalence of MetS in
mood and anxiety disorders might help physicians to
watch out for MetS in patients with mental disorders,
who have a higher risk of MetS. We hypothesized that
patients with bipolar I disorder might have the highest
prevalence of MetS among these patients because patients




The study was conducted from August 2008 to July 2009
in the psychiatric outpatient clinic of Chang Gung Memor-
ial Hospital, a medical center in northern Taiwan, and was
approved by the Institutional Review Board of the same
hospital. The investigators screened the medical charts of
psychiatric outpatients and excluded patients: 1) aged < 20
or > 60 years; 2) with psychotic disorders, such as schizo-
phrenia, schizoaffective disorder, delusional disorder, andother psychotic disorders; 3) with mental retardation, delir-
ium, dementia, and mental disorders due to general med-
ical conditions. Patients with a mental disorder due to a
general medical condition were excluded because patients
in this group were heterogeneous and might be treated by
a variety of medications. Therefore, the reasons for MetS
among these patients are complicated and unclear. Patients
with mood disorders with active psychotic symptoms or a
current manic episode in the index month were also ex-
cluded because these patients may have difficulty complet-
ing self-administered scales or cooperating with the study
process. The other outpatients were considered eligible
subjects and were assigned a number. Systematic sampling
was then used to draw one subject from 5 eligible subjects.
Written informed consent, based on the guidelines regu-
lated in the Declaration of Helsinki, was obtained from all
subjects prior to study enrollment.
Evaluation of mood and anxiety disorders
The Structured Clinical Interview for DSM-IV-text revi-
sion Axis I Disorders (SCID) [24,25] was used to diagnose
bipolar disorders, MDD, and anxiety disorders, including
panic disorder and/or agoraphobia, social phobia, simple
phobia, obsessive-compulsive disorder and post-traumatic
stress disorder and GAD. Patients with a lifetime history
of MDD were divided into three states based on the se-
verity of depression in the index month: a current major
depressive episode (MDE), partial remission of a MDE,
and full remission of a MDE. A current MDE was diag-
nosed based on the SCID and full remission was defined
as a score on the Hamilton Depression Rating Scale
(HAMD) ≤ 7 [26]. Bipolar disorders and MDD were com-
monly comorbid with anxiety disorders. If patients had
mood and anxiety disorders simultaneously, their diag-
noses were categorized as bipolar disorders or MDD, not
anxiety disorders, because the impacts of major mood epi-
sodes on patients might be greater than those of anxiety
symptoms, and prevention of these mood episodes is often
the treatment focus. Therefore, patients were divided into
bipolar I disorder, bipolar II disorder, MDD, anxiety-only
disorders, and no mood and/or anxiety disorders.
Evaluation of depression, anxiety, and somatic symptoms
In this study, three scales – the HAMD, the Depression
and Somatic Symptoms Scale (DSSS), and the Hospital
Anxiety and Depression Scale (HADS) – were used to
evaluate the severities of depression, anxiety, and somatic
symptoms [26-29]. The DSSS, a self-administered scale in-
cluding 12 items for depression (Depression Subscale; DS)
and 10 items for somatic symptoms (Somatic Subscale;
SS), was developed to monitor both depressive and som-
atic symptoms [27,28]. Its reliability and validity have been
reported in previous studies [27,28]. The HADS comprises






Figure 1 The model of mediation analysis. Note: The results of
paths b and c are shown in the regression models I and II of
Table 4, respectively. In path a, the relationship between the use of
antipsychotics and/or mood stabilizers and bipolar I disorder was
significant, but it was not possible to calculate the odds ratio because
all patients with bipolar I disorder were treated with antipsychotics
and/or mood stabilizers.
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for the HAMD, 0 to 36 for the DS, 0 to 30 for the SS, and
0 to 21 for both the HADS-D and HADS-A. A higher
score indicates a higher severity of symptoms for all
three scales.
Evaluation of metabolic syndrome and related factors
MetS was diagnosed based on the new International
Diabetics Federation definition [1], which includes central
obesity (waist circumference ≥ 90 cm in men and ≥ 80 cm
in women for Chinese subjects) or a body mass index
(BMI) > 30 kg/m2 plus any two of the following four
criteria: 1) elevated triglycerides (TG) (≥150 mg/dl or spe-
cific treatment for this lipid abnormality); 2) reduced
high-density lipoprotein (HDL) cholesterol (<40 mg/dl in
males; <50 mg/dl in females or specific treatment for this
lipid abnormality); 3) elevated blood pressure (BP) (sys-
tolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg or treat-
ment of previously-diagnosed hypertension); 4) elevated
fasting plasma glucose (FPG) (≥100 mg/dl or previously-
diagnosed type II diabetes).
An assistant investigator measured the body height
and weight of subjects using standard instruments. BMI
was then calculated. Some factors related to MetS were
also recorded, such as alcohol dependence or abuse diag-
nosed based on the SCID, smoking habit, a regular exer-
cise habit, pharmacotherapy factors, and other factors
including parents’ history of diabetes mellitus, past history
of psychiatric admission, and past history of attempted
suicide. Antipsychotic, mood stabilizer, and antidepressant
use were recorded, because the three psychotropics are
commonly used in mood and anxiety disorders and have
been reported to be related to MetS or weight gain [8-10].
The total numbers and costs of the three medication
categories as well as the total years of psychiatric phar-
macotherapy were calculated. Moreover, patients were
requested to report their weight gain since accepting psy-
chiatric pharmacotherapy (self-reported weight gain).
Statistical analysis
All statistical analyses were performed using SPSS for
Windows 15.0. The independent t test, chi-square test,
Pearson’s correlation, and Spearman’s correlation test
were used where appropriate. In order to clarify the im-
pacts of diagnosis and pharmacotherapy on MetS, Baron
and Kenny’s procedures for mediation analyses, which
were performed by multiple logistic regressions with
Wald and forward selection, were used (Figure 1). In the
first model (path c), the dependent variable was MetS
and the independent variables were five demographic
variables (age, gender, educational years, marital status,
and employment) and psychiatric disorders (bipolar I dis-
order, bipolar II disorder, life-time history of MDD, any
anxiety disorder, alcohol abuse or dependence). In thesecond model (path b), the dependent variable was MetS
and the independent variables were five demographic vari-
ables and pharmacotherapy factors (years of pharmaco-
therapy, number of medications, use of antidepressants,
use of mood stabilizers, use of antipsychotics, and use of
antipsychotics and/or mood stabilizers). In the third
model (path a), the dependent variable was the significant
pharmacotherapy factor in the second model and the in-
dependent variables were five demographic variables and
the significant psychiatric disorders in the first model. In
the fourth model, the dependent variable was MetS and
the independent variables were five demographic vari-
ables, the significant psychiatric disorders in the first
model, the significant pharmacotherapy factor in the sec-
ond model, and other factors (including parents’ history of
diabetes mellitus, suicide attempt history, and history of
psychiatric admission).
BMI was an important factor related to MetS and the
first criterion of MetS. To understand whether psy-
chiatric diagnoses and pharmacological factors are still
significant after adding BMI as an independent factor,
the fifth model was performed. The dependent variable
was MetS and independent variables were BMI and all
independent factors in the fourth model. In all statistical




During the study period, a total of 2201 patients (880
males, 1321 females; mean age 46.6 ± 14.7 years) were
screened and 1054 patients (479 males, 575 females;
mean age 48.8 ± 17.9 years) were excluded due to the ex-
clusion criteria (475 patients with psychotic disorders,
198 patients with dementia or aged > 60 years, 5 patients
with a current manic episode, and 376 patients for other
reasons, including 77 patients with mental retardation, 8
with delirium, 229 with mental disorders due to general
medical conditions, and 62 aged < 20 years). Among the
1147 eligible subjects (401 males, 746 females; mean age
44.6 ± 10.4 years), 229 patients were enrolled by system-
atic sampling. Their scores in the three scales or their sub-
scales, the indices of MetS, and the demographic variables
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positively skewed and triglycerides and fasting plasma
glucose had obvious leptokurtic distributions, these con-
tinuous variables were transformed to categorical variables
for diagnosing MetS. Among the 229 subjects, 51 (22.3%)
fulfilled the criteria for MetS. Compared with subjects
without MetS, subjects with MetS were of significantly
older age, had fewer years of education, took a greater
number of medications with a higher cost, and had greater
self-reported weight gain and higher indices of MetS.
There were no significant differences in the scores of the
three scales or subscales between subjects with and with-
out MetS, with the exception of the SS score.
Diagnosis and metabolic syndrome
Table 2 shows the prevalence of MetS with different
diagnoses. Bipolar I disorder patients had the highestTable 1 Indices of metabolic syndrome, scores of the three ps
with and without metabolic syndrome†
Total sample (n = 229)
Waist circumference (cm) 83.5 ± 10.0
BMI 24.2 ± 4.0
Triglycerides (mg/dL) 163.7 ± 205.3
HDL (mg/dL) 54.1 ± 13.8
Systolic BP (mmHg) 118.5 ± 161
Diastolic BP (mmHg) 78.1 ± 10.8
Fasting plasma glucose (mg/dL) 93.3 ± 19.5
DS 13.8 ± 8.2
SS 10.2 ± 6.4
HADS-D 8.3 ± 4.9
HADS-A 9.7 ± 4.7
HAMD 11.8 ± 6.9
Antipsychotics (Yes; %) 53 (23.1%)
Mood stabilizers (Yes; %) 28 (12.2%)
Antidepressants (Yes; %) 205 (89.5%)
Number of medications 1.6 ± 0.8
Medication cost per day (NTD) 47.8 ± 67.8
Years of pharmacotherapy 4.4 ± 4.3
Self-reported weight gain (kg) 4.1 ± 6.7
Age (years) 44.2 ± 9.9
Years of education 11.4 ± 3.2
Gender (Female) 144 (62.9%)
Paid employment (Yes) 139 (60.7%)
Married (Yes) 160 (69.6%)
Note: DSSS = Depression and Somatic Symptoms Scale; DS = depression subscale of
Depression Scale; HADS-D = depression subscale of the HADS; HADS-A = anxiety sub
mass index; HDL = high-density lipoprotein; NTD = new Taiwan Dollar (about 30 NTD
*p < 0.05; **p < 0.01.
†Hypertension under treatment: n = 24; previously-diagnosed type II diabetes: n = 10prevalence of MetS, followed by bipolar II disorder and
MDD. Spearman’s correlation analysis showed that the
percentages of MetS among the five categories were signifi-
cantly correlated with the percentages of patients using
antipsychotics (correlation coefficient r = 0.90, p = 0.04),
those using mood stabilizers (r = 0.98, p < 0.01), those using
antipsychotics and/or mood stabilizers (r = 0.90, p = 0.04),
and the number of medications (r = 1, p < 0.001). However,
the correlations with p = 0.04 became insignificant after
using Bonferonni correction (significance should reach
p < 0.0125) for multiple comparisons.
Table 2 also shows the percentage of fulfilled MetS
indices among the patients with different diagnoses.
In the total sample, central obesity had the highest
percentage, followed by elevated BP, elevated TG, re-
duced HDL, and elevated FPG. However, in the subjects
with bipolar I or II disorder, the percentages of elevatedychometric scales, and demographic variables in subjects
Metabolic syndrome
Yes (n = 51; 22.3%) No (n = 178; 77.7%)
94.5 ± 8.5** 80.4 ± 8.0
28.3 ± 3.5** 23.1 ± 3.3
305.9 ± 349.5** 122.9 ± 110.9
43.8 ± 9.5** 57.1 ± 13.4
129.3 ± 15.5** 115.4 ± 14.9
85.0 ± 10.5** 76.1 ± 10.1
107.1 ± 35.3** 89.4 ± 8.4
13.2 ± 7.5 13.9 ± 8.4
8.7 ± 4.7* 10.6 ± 6.7
9.1 ± 5.3 8.1 ± 4.8
9.0 ± 4.4 10.0 ± 4.7
11.7 ± 6.1 11.8 ± 7.1
18 (35.3%)* 35 (19.7%)
10 (19.6%) 18 (10.1%)
45 (88.2%) 160 (89.9%)
1.8 ± 0.8* 1.5 ± 0.8
70.7 ± 87.4* 41.2 ± 59.7
5.2 ± 5.1 4.1 ± 4.1
7.5 ± 7.7** 3.1 ± 6.1
47.3 ± 9.3* 43.3 ± 10.0
10.5 ± 3.1* 11.6 ± 3.3
29 (56.9%) 115 (64.6%)
28 (54.9%) 111 (62.4%)
35 (68.6%) 125 (70.2%)
the DSSS; SS = somatic subscale of the DSSS; HADS = Hospital Anxiety and
scale of the HADS; HAMD = Hamilton Depression Rating Scale; BMI = body
= 1 US dollar).
; treatment for elevated TG: n = 10; treatment for reduced HDL: n = 10.











disorders (n = 36)
No mood and/or anxiety
disorders (n = 21)
MetS 22.3 (51) 46.7 (7) 25.0 (4) 22.0 (31) 16.7 (6) 14.3 (3)
Central obesity 46.3 (106) 73.3 (11) 62.5 (10) 45.5 (64) 41.7 (15) 28.6 (6)
BMI > 30 kg/m2 8.3 (19) 13.3 (2) 18.8 (3) 7.8 (11) 8.3 (3) 0 (0)
Elevated TG 35.8 (82) 60.0 (9) 37.5 (6) 36.9 (52) 30.6 (11) 19.0 (4)
Reduced HDL 30.6 (70) 46.7 (7) 37.5 (6) 29.8 (42) 27.8 (10) 23.8 (5)
Elevated BP 38.4 (88) 40.0 (6) 25.0 (4) 41.1 (58) 38.9 (14) 28.6 (6)
Elevated FPG 18.3 (42) 13.3 (2) 12.5 (2) 20.6 (29) 13.9 (5) 19.0 (4)
Antipsychotics 23.1 (53) 80.0 (12) 25.0 (4) 22.7 (32) 8.3 (3) 9.5 (2)
Mood stabilizers 12.2 (28) 93.3 (14) 31.3 (5) 6.4 (9) 0 (0) 0 (0)
Antipsychotics and/or mood stabilizers 27.9 (64) 100.0 (15) 50.0 (8) 25.5 (36) 8.3 (3) 9.5 (2)
Antidepressants 89.5 (205) 40.0 (6) 81.3 (13) 95.7 (135) 94.4 (34) 81.0 (17)
Number of medications 1.6 ± 0.8 2.4 ± 0.9 1.7 ± 1.1 1.6 ± 0.8 1.4 ± 0.6 1.1 ± 0.7
Note: MetS = Metabolic syndrome; BMI = body mass index; TG = triglycerides; Elevated BP = elevated systolic or diastolic blood pressure; FPG = fasting plasma
glucose; HDL = high-density lipoprotein.
†Case numbers are shown in brackets.
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vated BP.
Among 141 MDD patients, subjects with full remis-
sion (25.9%; 7/27) had the highest percentage of MetS,
followed by those with a current MDE (24.4%; 10/41)
and partial remission of MDE (19.2%; 14/73); however,
the MetS percentages of the three states were not signifi-
cantly different. There was also no significant correlation
between the severity of depression, anxiety, or somatic
symptoms (the HAMD, DS, SS, HADS-D, HADS-A scores)
and the MetS indices (waist circumference, BMI, FPG, TG,
BP, and HDL) among patients with MDD, except for a
correlation of HADS-A (r = -0.25, p < 0.01) and HAMD
(r = -0.21, p = 0.01) with waist circumference.
Pharmacotherapy
Among 229 subjects, antidepressants were prescribed in
205 (89.5%) subjects. The most commonly-used anti-
depressant was paroxetine (percentage and mean dosage:
24.4%; 24.0 ± 11.1 mg), followed by trazodone (23.9%;
56.8 ± 30.6 mg), duloxetine (17.6%; 57.1 ± 24.8 mg),
escitalopram (16.6%; 10.4 ± 4.7 mg), fluoxetine (12.2%;
36.0 ± 12.9 mg), and venlafaxine (10.2%; 128.6 ± 67.7 mg).
Antipsychotics were prescribed in 53 (23.1%) subjects.
Quetiapine (43.4%; 118.5 ± 100.3 mg) was the most com-
monly-used antipsychotic, followed by sulpiride (35.8%;
81.6 ± 41.5 mg) and olanzapine (11.3%; 5.8 ± 2.0 mg).
Twenty-eight (12.2%) subjects were treated with mood
stabilizers, including valproate (67.9%; 636.8 ± 305.9 mg),
lamotrigine (17.9%; 200 ± 122.5 mg) and lithium (14.3%;
525.0 ± 150.0 mg).
Subjects being treated with antipsychotics had a higher
risk of MetS than those who were free from treatmentwith antipsychotics (Table 3). Patients being treated
with antipsychotics and/or mood stabilizers had a sig-
nificantly higher risk of MetS (35.9% vs. 17.0%, Odds
Ratio = 2.75, 95% CI = 1.43–5.27, p = 0.004) compared
with patients who were not being treated with antipsy-
chotics and/or mood stabilizers. There was no significant
difference in the risk of MetS between those who were
treated with antidepressants and those who were not.
Correlations of demographic variables, severity of
depression, anxiety, and somatic symptoms with MetS
indices
The correlations of the HAMD, DS, SS, HADS-A, and
HADS-D with the MetS indices were not significant,
with the exception of the correlation of HADS-A with
waist circumference (r = -0.14, p = 0.04). Age was sig-
nificantly correlated with FPG (r = 0.29, p < 0.001), TG
(r = 0.16, p = 0.02), systolic BP (r = 0.31, p < 0.001), diastolic
BP (r = 0.14, p = 0.04), BMI (r = 0.17, p = 0.01), and waist
circumference (r = 0.23, p < 0.001). Educational years
was correlated with FPG (r = - 0.26, p < 0.001), systolic BP
(r = - 0.26, p < 0.001), BMI (r = - 0.22, p = 0.001), and waist
circumference (r = -0.19, p = 0.003). Number of medi-
cations was correlated with TG (r = 0.19, p = 0.004), BMI
(r = 0.20, p = 0.002) and waist circumference (r = 0.17,
p = 0.01). Years of pharmacotherapy was not significantly
correlated with the indices of MetS, with the exception of
FPG (r = 0.14, p = 0.04).
Other factors related to metabolic syndrome
Subjects with alcohol abuse or dependence had a tendency
towards a higher MetS prevalence (33.3% vs. 19.8%,
p = 0.07) as compared with those without (Table 3). There
Table 3 Chi-square comparison of the percentages of patients with metabolic syndrome between groups‡
Yes† No p Odds ratio (95% CI)
Bipolar I 46.7 (7/15) 20.6 (44/214) 0.03 3.38 (1.16–9.23)
Bipolar II 25.0 (4/16) 22.1 (47/213) 0.76 1.18 (0.36–3.82)
Major depressive disorder 22.0 (31/141) 22.7 (20/88) 1.00 0.96 (0.51–1.81)
Any anxiety disorders 18.4 (26/141) 28.4 (25/88) 0.10 0.57 (0.30–1.07)
Alcohol abuse or dependence 33.3 (14/42) 19.8 (37/187) 0.07 2.03 (0.97–4.23)
Age > 45 years 29.7 (35/118) 14.4 (16/111) < 0.01 2.50 (1.29–4.85)
Exercise 26.5 (27/102) 18.9 (24/127) 0.20 1.55 (0.83–2.89)
Smoking 20.0 (12/60) 23.1 (39/169) 0.72 0.83 (0.40–1.72)
Weight gain 29.3 (39/133) 12.5 (12/96) < 0.01 2.90 (1.43–5.91)
Use of antipsychotics 34.0 (18/53) 18.8 (33/176) 0.02 2.23 (1.13–4.41)
Use of mood stabilizers 35.7 (10/28) 20.4 (41/201) 0.09 2.17 (0.93–5.05)
Use of antidepressants 22.0 (45/205) 25.0 (6/24) 0.80 0.84 (0.32–2.25)
Parents’ history of diabetes mellitus 30.4 (21/69) 18.7 (30/160) 0.06 1.90 (0.99-3.63)
History of suicide attempt 25.7 (18/70) 20.8 (33/159) 0.49 1.32 (0.68-2.55)
History of psychiatric admission 45.0 (9/20) 20.1 (42/209) 0.02 3.25 (1.27-8.36)
†The percentage in the “yes” column represents the percentage of MetS in patients with a mental disorder (such as bipolar I disorder) or a variable (such as smoking).
In the bracket, the numerator represents the case number of the patients with MetS.
‡Data with significant difference between the two groups are presented in boldface.
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between subjects who exercised and those who did not
and between subjects who smoked and those who did
not. One-hundred and thirty-three subjects (58.1%)
reported weight gain (8.2 ± 5.7 kg) after accepting psy-
chiatric pharmacotherapy, 34 (14.8%) reported weight
loss (4.6 ± 2.9 kg), and 62 (27.1%) reported no change
in body weight. Compared with subjects without self-
reported weight gain, the percentage of MetS was sig-
nificantly higher in subjects with self-reported weight
gain. Weight change (kg) was significant correlated





Bipolar I disorder 1.31
Model II and IV†
Age 0.05




†The results of models II and IV were the same.
‡The results shown in Table 4 were obtained by multiple logistic regressions with W
the independent variables were five demographic variables and psychiatric disorde
variables were five demographic variables and pharmacotherapy factors. In Model I
demographic variables, the significant psychiatric disorders in the first model, the s
(including parents’ history of diabetes mellitus, suicide attempt history, and historyp < 0.01). There was a trend (p = 0.06) that a father and/
or mother with diabetes mellitus resulted in a higher risk
of MetS. Subjects with a history of psychiatric admission
had a significantly increased risk of MetS. A history of
attempted suicide was not a significant factor in MetS.
Factors independently predicting MetS
Table 4 shows the results of mediation analysis. In the
first model, subjects of older age and those with bipolar
I disorder had a higher risk of MetS. In the second
model, use of antipsychotics and/or mood stabilizers,
which exceeded the impact of an older age on the risk ofe among psychiatric outpatients with mood and anxiety
Wald Odds ratio (95% CI) p-value
6.65 1.05 (1.01–1.08) 0.01
5.48 3.71 (1.24–11.11) 0.02
7.97 1.05 (1.02–1.09) 0.005
11.08 3.17 (1.61–6.25) 0.001
41.46 1.55 (1.36–1.77) < 0.001
4.51 1.05 (1.00–1.10) 0.04
ald and forward selection. In Model I, the dependent variable was MetS and
rs. In Model II, the dependent variable was MetS and the independent
V, the dependent variable was MetS and the independent variables were five
ignificant pharmacotherapy factor in the second model, and other factors
of psychiatric admission).
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and was the most significant factor independently pre-
dicting MetS. In the third model, there was a significant
relationship between the use of antipsychotics and/or
mood stabilizers and bipolar I disorder. However, it was
not possible to calculate the odds ratio because all patients
with bipolar I disorder were treated with antipsychotics
and/or mood stabilizers (Table 2). The results of the
fourth model, which were the same as the results of the
second model, demonstrated that use of antipsychotics
and/or mood stabilizers was a significant factor to predict
MetS after controlling for psychiatric diagnoses and other
factors.
In the fifth model, BMI was the most significant factor
in the prediction of MetS; however, the use of antipsy-
chotics and/or mood stabilizers and bipolar I disorder
was not significant.
Discussion
After controlling for the demographic variables, the first
regression model found that bipolar I disorder could
predict MetS. The second regression model demon-
strated that use of antipsychotics and/or mood stabi-
lizers could predict MetS. Moreover, all patients with
bipolar I disorder were treated with antipsychotics and/
or mood stabilizers (Table 2). The fourth model found
that use of antipsychotics and/or mood stabilizers could
independently predict MetS after controlling for the
demographic variables, psychiatric diagnoses, and other
factors. Therefore, use of antipsychotics and/or mood
stabilizers might have a mediation effect on the relation-
ship of bipolar I disorder and MetS in this study. How-
ever, more evidence may be required to support this
result. Previous studies have reported that some anti-
psychotics and mood stabilizers are related to an increase
in the risk of lipid abnormality [30-32]. Future studies
should consider that pharmacotherapy factors might have
mediation effects on the relationship of psychiatric diag-
noses and MetS. Bipolar I disorder had the highest risk of
MetS in this study. This might partially result from the
fact that patients with bipolar I disorder had the highest
percentage of being treated with antipsychotics and/or
mood stabilizers. Conversely, the prevalence of MetS
among patients with only anxiety disorders (16.7%) or
patients without any mood and anxiety disorders (14.3%)
was close to the prevalence of MetS reported in a general
population study in Taiwan (14.3%) [33]. Lower percent-
ages of patients in the two groups were treated with anti-
psychotics (<10%) and none with mood stabilizers, and
the number of medications was lower (Table 2). Moreover,
the prevalence of MetS in the five groups was correlated
with the percentage of patients taking antipsychotics and/
or mood stabilizers as well as the number of medica-
tions. These results demonstrate that pharmacotherapymay have an important role in the etiology of MetS among
these psychiatric outpatients.
In the fifth model, use of antipsychotics and/or mood
stabilizers and bipolar I disorder was not significant after
adding BMI as an independent variable. This might par-
tially be due to BMI being the first criterion for MetS.
Although this regression model found that BMI was the
most significant factor for the prediction of MetS, this
does not mean that pharmacological factors and psy-
chiatric disorders are not important, because pharmaco-
logical factors and psychiatric disorders might be possible
underlying causes of elevated BMI. Many previous studies
have reported that some antipsychotics and mood stabi-
lizers are associated with weight gain and abnormal lipid
indices [8-10,30-32]. Moreover, some psychiatric disorders
are related to changes in appetite and dieting behavior,
unhealthy lifestyles, and dysfunctions of the endocrine
system [8-12,34,35]. Future studies should further clarify
the underlying causes of elevated BMI and the relation-
ships between BMI, pharmacotherapy, and psychiatric dis-
orders. In clinical practice, physicians should encourage
patients to control BMI within an appropriate range.
Twenty-two percent of the MDD outpatients had MetS.
This result was close to that of Richter’s report, which
showed that 25% of depressive inpatients had MetS [36].
No significant difference was noted in the percentage of
MetS between the three depressive states (MDE, partial
remission, and full remission). There was also no signifi-
cant correlation of the severity of depression, anxiety, or
somatic symptoms with HDL, TG, FPG, or BP in the total
sample and in patients with MDD. In fact, some studies
have also demonstrated no significant correlation of de-
pression and anxiety with MetS [19,20]. Two possibilities
were assumed to explain the lack of a significant relation-
ship between depressive states and MetS. First, the process
of forming MetS might require a longer duration, such as
several months or years; however, depressive severity
might change within a shorter time, such as several days
or weeks. Second, the impact of pharmacotherapy or other
factors might be greater than that of depressive severity.
However, these assumptions require more evidence.
There are several points worthy of note: 1) the preva-
lence of MetS in the total sample was higher (22.3% vs.
14.3%) than that reported in a general population study
of MetS prevalence in Taiwan, diagnosed based on the
IDF criteria [33]. Physicians should be aware of the risk
of MetS when treating these outpatients. 2) The ranking
of abnormal percentages of MetS indices in the total
sample, MDD patients, and only anxiety disorder patients
(Table 2) was similar to the results of an investigation into
the prevalence of MetS in the general population of
Taiwan, which demonstrated that the ranking of abnormal
percentages was central obesity > elevated BP > elevated
TG > reduced HDL > elevated FPG [33]. However, in the
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centages of TG and HDL were higher than that of elevated
BP in this study. Some previous studies have also shown
that patients with bipolar I disorder have a higher percent-
age of elevated TG and reduced HDL than of elevated BP
[4,37]. 3) Patients treated with antipsychotics had a higher
risk of MetS (Table 3). The three most common antipsy-
chotics in this study have been reported to be associated
with increased abnormality of some MetS indices [30,38].
The dosage of antipsychotics in this study was lower than
the suggested dosage for treating schizophrenia. This im-
plied that even when using only a low dosage of antipsy-
chotics, physicians still need to be aware of the indices of
MetS. 4) Weight change was significantly correlated with
HDL and diastolic BP. Moreover, the prevalence of MetS
was significantly higher in subjects with self-reported
weight gain post-pharmacotherapy. Physicians in clinical
practice should educate patients about the clinical mean-
ing of weight change and monitor it. 5) In univariate
analysis, patients with MetS were treated with more medi-
cations (Table 1). One study reported that combination
treatment of antipsychotics and mood stabilizers resulted
in greater weight gain than mono-therapy with an anti-
psychotic or mood stabilizer among patients with bipolar I
disorder [8]. Therefore, physicians should consider the
impact of the synergistic effect of using multiple medica-
tions on MetS.
There are several methodological issues or limitations
of this study to be addressed. 1) Because of limited
budget for this study, selective sampling, which led to a
small sample size within the disorder categories, was
used. The small sample size hindered further analysis of
the impact of each medication. Moreover, the small
sample size meant that the findings of this study are not
sufficiently robust and should be further examined in
future studies. 2) This study was performed in a medical
center and some exclusion criteria were established to
prevent confounding factors. Bias might have been intro-
duced during the enrollment process. 3) This study was a
neutral clinical study and subjects might be treated with
different medications and dosages. Only the three most
common medications for mood and anxiety disorders
were considered. Moreover, even in the same medication
category, different medications carry different risks of
MetS. 4) Although the sample sizes of patients with bipo-
lar disorders and only anxiety disorders were small, this
study simultaneously presented the prevalence of MetS
among the five groups and demonstrated the impacts of
diagnosis and pharmacotherapy. 5) The study only en-
rolled patients aged 20 to 60 years. Geriatric patients, who
had a higher risk of MetS, were excluded. This might
cause bias, and the percentage of MetS might be under-
estimated. 6) MetS in patients with schizophrenia was
not investigated because this issue has been addressedpreviously in many studies. 7) The study did not include
subjects without psychiatric disorders as a control group.
Conclusion
BMI was the most important factor related to MetS, based
on the fifth regression model. Pharmacotherapy might be
one of underlying causes of elevated BMI. Based on the
fourth regression model, pharmacotherapy was an import-
ant factor independently predicting MetS among psy-
chiatric outpatients with mood and anxiety disorders.
Subjects with bipolar I disorder had the highest prevalence
of MetS among these patients. The percentages of MetS
among the five groups were correlated with the percent-
ages of patients being treated with antipsychotics and/or
mood stabilizers. Among patients with MDD, the severity
of depression, anxiety, and somatic symptoms were not
significantly correlated with the indices of MetS. Patients
with only anxiety disorders or without any mood or anxiety
disorders, who had the lowest percentage of being treated
with antipsychotics or mood stabilizers, had the lowest
prevalence of MetS. However, explanation of the results
should be tentative because of the small sample size of this
study. These results should be further examined by future
studies. Future studies of the risk of MetS should further
explore the interaction between pharmacotherapy and
mental diagnoses.
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